For the full year, the company billed 41,586 tissue-based units and 45,700 liquid-based units, representing growth of 31% and 28%, respectively. Cash balance at year-end was $46.8M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks